We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+3.84%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$135M
AUM Growth
-$22M
Cap. Flow
-$25.1M
Cap. Flow %
-18.68%
Top 10 Hldgs %
55.15%
Holding
156
New
39
Increased
27
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
MSDAU
MSD Acquisition Corp. Unit
MSDAU
+$5.02M
2
WORK
Slack Technologies, Inc.
WORK
+$3.37M
3
RP
RealPage, Inc.
RP
+$3.36M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$3.33M
5
ATHM icon
Autohome
ATHM
+$1.65M

Top Sells

Rank Stock Value
1
DELL icon
Dell
DELL
+$26.3M
2
TIF
Tiffany & Co.
TIF
+$6.72M
3
ACIA
Acacia Communications Inc
ACIA
+$3.24M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$3.07M
5
BIDU icon
Baidu
BIDU
+$2.66M

Sector Composition

Rank Sector Weight
1 Technology 31.89%
2 Healthcare 28.92%
3 Financials 8.63%
4 Consumer Discretionary 6.74%
5 Communication Services 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
51
Black Diamond Therapeutics
BDTX
$120M
$649K 0.48%
+26,770
New +$722K
ALT icon
52
Altimmune
ALT
$583M
$648K 0.48%
45,866
-26,512
-37% -$429K
ADVM
53
DELISTED
Adverum Biotechnologies
ADVM
$640K 0.48%
6,491
+1,038
+19% +$125K
RCKT icon
54
Rocket Pharmaceuticals
RCKT
$382M
$636K 0.47%
14,336
-10,231
-42% -$562K
TVTX icon
55
Travere Therapeutics
TVTX
$5.68B
$615K 0.46%
+24,622
New +$680K
SPRY icon
56
ARS Pharmaceuticals
SPRY
$591M
$614K 0.46%
+14,067
New +$666K
NVTA
57
DELISTED
Invitae Corporation
NVTA
$613K 0.46%
16,039
+626
+4% +$28.5K
NVAX icon
58
Novavax
NVAX
$1.31B
$606K 0.45%
3,341
-2,381
-42% -$474K
NRIX icon
59
Nurix Therapeutics
NRIX
$2.69B
$598K 0.44%
+19,222
New +$727K
LONA
60
LeonaBio Inc
LONA
$71.6M
$590K 0.44%
3,206
– –
RLAY icon
61
Relay Therapeutics
RLAY
$4.38B
$583K 0.43%
16,876
+1,901
+13% +$82.5K
FMTX
62
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$578K 0.43%
20,630
+2,378
+13% +$85.8K
IOVA icon
63
Iovance Biotherapeutics
IOVA
$2.94B
$575K 0.43%
18,163
-2,260
-11% -$93.7K
ORIC icon
64
Oric Pharmaceuticals
ORIC
$1.42B
$547K 0.41%
+22,333
New +$706K
CNST
65
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$544K 0.4%
23,271
-8,610
-27% -$261K
KYMR icon
66
Kymera Therapeutics
KYMR
$9.11B
$542K 0.4%
13,941
-3,176
-19% -$191K
STOK icon
67
Stoke Therapeutics
STOK
$2.13B
$532K 0.4%
13,692
-3,976
-23% -$226K
RYTM icon
68
Rhythm Pharmaceuticals
RYTM
$7.77B
$528K 0.39%
+24,809
New +$720K
BCEL
69
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$526K 0.39%
34,301
+3,477
+11% +$56.5K
SLDB icon
70
Solid Biosciences
SLDB
$949M
$506K 0.38%
+6,104
New +$675K
NKTX icon
71
Nkarta
NKTX
$167M
$491K 0.36%
14,927
-9,061
-38% -$433K
OLMA icon
72
Olema Pharmaceuticals
OLMA
$911M
$480K 0.36%
+14,455
New +$619K
ACAD icon
73
Acadia Pharmaceuticals
ACAD
$5.07B
$428K 0.32%
16,590
+2,246
+16% +$98.9K
NVO
74
Novo Nordisk
NVO
$207B
$345K 0.26%
10,226
-5,164
-34% -$184K
MBT
75
DELISTED
Mobile TeleSystems Public Joint Stock Company American Depositary Shares (Each representing 2 Shares
MBT
$343K 0.25%
41,134
+8,875
+28% +$78K
1 2
3
4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q1 2021 Portfolio in Review

As of Q1 2021, HighVista Strategies held 156 positions worth $135M, down 14% from $157M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

HighVista Strategies withdrew a net $25.1M in Q1 2021, closing 31 positions and reducing 28 holdings. Its most notable exit was Tiffany & Co., an estimated $6.72M position sold in full.

By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 37% a quarter earlier, followed by Healthcare and Financials.

Against the trend, HighVista Strategies opened a new position in MSD Acquisition Corp. Unit worth $5.08M.

  • HighVista Strategies's largest Q1 2021 buy was MSD Acquisition Corp. Unit: 500,000 shares worth $5.08M.
  • HighVista Strategies added most to Alibaba in Q1 2021, an estimated $700K increase.
  • HighVista Strategies's biggest Q1 2021 reduction was Dell, cutting an estimated $26.3M.
  • HighVista Strategies fully exited Tiffany & Co. in Q1 2021, selling an estimated $6.72M.
  • HighVista Strategies's ten largest holdings make up 55% of its $135M portfolio in Q1 2021.
  • HighVista Strategies opened 39 new positions and closed 31 in Q1 2021.
  • HighVista Strategies's portfolio value fell 14% quarter-over-quarter to $135M.

Based on HighVista Strategies's 13F filing for Q1 2021, filed 17 May 2021.